{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:58:48Z","timestamp":1792717128785,"version":"4.5.0"},"reference-count":51,"publisher":"Bentham Science Publishers Ltd.","issue":"9","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CAR"],"published-print":{"date-parts":[[2021,1,15]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>We have recently identified Huntingtin (Htt), the pathogenic protein in\nHuntington\u2019s disease, as a mediator of Alzheimer\u2019s disease (AD) pathology in an amyloid precursor protein\n(APP) knock-in mouse model of AD. That finding prompted us to examine if Htt is accumulated in\nthe brains of AD patients and in which cell type Htt is present in the AD brain.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>To investigate whether location and levels of Htt are affected in hippocampus and frontal cortex\nin AD.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Brains from AD patients (n=11) and controls (n=11) were stained for Htt using immunohistochemistry\nand signal intensity of Htt was quantified and localized in subregions and neurons. Confocal\nmicroscopy was used to characterize neuronal Htt localisation and its relationship with tau tangles and\nastrocytes.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Htt levels were increased in neuronal cells in the granular layer of the dentate gyrus, in CA1\nand CA3 in hippocampus and in layer III of the frontal cortex. Htt was found in the soma, perinuclear\nspace, thin neurites and nucleus of pyramidal neurons. Htt was present in neurons containing tau tangles\nbut did not colocalize with astrocytes.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p> Htt accumulates in pyramidal neuron-rich areas including hippocampal subregions associated\nwith memory and frontal cortex layer III. The accumulation of Htt in AD shows distinct cellular\nand morphological patterns and is not present in astrocytes. Clearly, further research is warranted to elucidate\nthe role of Htt as a mediator of AD pathology and the potential use of Htt as a target in future\ntherapeutic strategies.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1567205017666201203125622","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T07:01:25Z","timestamp":1607065285000},"page":"858-867","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Huntingtin Levels are Elevated in Hippocampal Post-Mortem Samples of Alzheimer\u2019s Disease Brain"],"prefix":"10.2174","volume":"17","author":[{"given":"Michael","family":"Axenhus","sequence":"first","affiliation":[{"name":"Division of Neurogeriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Winblad","sequence":"additional","affiliation":[{"name":"Division of Neurogeriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars O.","family":"Tjernberg","sequence":"additional","affiliation":[{"name":"Division of Neurogeriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Schedin-Weiss","sequence":"additional","affiliation":[{"name":"Division of Neurogeriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","author":"Prince M.J.","year":"2015","unstructured":"Prince M.J.;  World Alzheimer Report The Global Impact of Dementia 2015\n                     https:\/\/www.alz.co.uk\/research\/world-report-20152015","journal-title":"World Alzheimer Report"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S1474-4422(18)30403-4","volume":"18","author":"Nichols E.","year":"2019","unstructured":"Nichols E.; Szoeke C.E.I.; Vollset S.E.; GBD 2016 Dementia Collaborators Global, regional, and national burden of Alzheimer\u2019s disease and other dementias, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019,18(1),88-106","journal-title":"Lancet Neurol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S1474-4422(16)00062-4","volume":"15","author":"Winblad B.","year":"2016","unstructured":"Winblad B.; Amouyel P.; Andrieu S.; Defeating Alzheimer\u2019s disease and other dementias: a priority for European science and society. Lancet Neurol 2016,15(5),455-532","journal-title":"Lancet Neurol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2016.07.150","volume":"13","author":"Wimo A.","year":"2017","unstructured":"Wimo A.; Guerchet M.; Ali G-C.; The worldwide costs of dementia 2015 and comparisons with 2010. Alzheimers Dement 2017,13(1),1-7","journal-title":"Alzheimers Dement"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1080\/13543784.2017.1323868","volume":"26","author":"Mehta D.","year":"2017","unstructured":"Mehta D.; Jackson R.; Paul G.; Shi J.; Sabbagh M.; Why do trials for Alzheimer\u2019s disease drugs keep failing? A discontinued drug perspective for 2010-2015. Expert Opin Investig Drugs 2017,26(6),735-739","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/1756285612461679","volume":"6","author":"Yiannopoulou K.G.","year":"2013","unstructured":"Yiannopoulou K.G.; Papageorgiou S.G.; Current and future treatments for Alzheimer\u2019s disease. Ther Adv Neurol Disorder 2013,6(1),19-33","journal-title":"Ther Adv Neurol Disorder"},{"key":"ref=7","author":"Brotchie J.","year":"2011","unstructured":"Brotchie J.; Bezard E.; Jenner P.;  Pathophysiology, pharmacology and biochemistry of dyskinesia 2011","journal-title":"Pathophysiology, pharmacology and biochemistry of dyskinesia"},{"key":"ref=8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-05336-7","volume":"5070","author":"Daldin M.","year":"2017","unstructured":"Daldin M.; Fodale V.; Cariulo C.;  Polyglutamine expansion affects huntingtin conformation in multiple Huntington\u2019s disease models  Sci Rep 7(1): 2017,5070","journal-title":"Polyglutamine expansion affects huntingtin conformation in multiple Huntington\u2019s disease models  Sci Rep 7(1):"},{"key":"ref=9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112262","volume":"9","author":"Fodale V.","year":"2014","unstructured":"Fodale V.; Kegulian N.C.; Verani M.; Polyglutamine- and temperature-dependent conformational rigidity in mutant huntingtin revealed by immunoassays and circular dichroism spectroscopy. PLoS One 2014,9(12)","journal-title":"PLoS One"},{"key":"ref=10","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2011.112","volume":"2","author":"Bano D.","year":"2011","unstructured":"Bano D.; Zanetti F.; Mende Y.; Nicotera P.; Neurodegenerative processes in Huntington\u2019s disease. Cell Death Dis 2011,2","journal-title":"Cell Death Dis"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.15252\/embj.201490808","volume":"34","author":"El-Daher M-T.","year":"2015","unstructured":"El-Daher M-T.; Hangen E.; Bruy\u00e8re J.; Huntingtin proteolysis releases non-polyQ fragments that cause toxicity through dynamin 1 dysregulation. EMBO J 2015,34(17),2255-2271","journal-title":"EMBO J"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"e2099","DOI":"10.1212\/WNL.0000000000005690","volume":"90","author":"Aziz N.A.","year":"2018","unstructured":"Aziz N.A.; van der Burg J.M.M.; Tabrizi S.J.; Landwehrmeyer G.B.; Overlap between age-at-onset and disease-progression determinants in Huntington disease. Neurology 2018,90(24),e2099-e2106","journal-title":"Neurology"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1038\/mp.2015.81","volume":"20","author":"Tan Z.","year":"2015","unstructured":"Tan Z.; Dai W.; van Erp T.G.M.; Huntington\u2019s disease cerebrospinal fluid seeds aggregation of mutant huntingtin. Mol Psychiatry 2015,20(11),1286-1293","journal-title":"Mol Psychiatry"},{"key":"ref=14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0172762","volume":"12","author":"Niemel\u00e4 V.","year":"2017","unstructured":"Niemel\u00e4 V.; Landtblom A-M.; Blennow K.; Sundblom J.; Tau or neurofilament light-Which is the more suitable biomarker for Huntington\u2019s disease? PLoS One 2017,12(2)","journal-title":"PLoS One"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/jnc.13719","volume":"139","author":"Rodrigues F.B.","year":"2016","unstructured":"Rodrigues F.B.; Byrne L.; McColgan P.; Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington\u2019s disease. J Neurochem 2016,139(1),22-25","journal-title":"J Neurochem"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1006\/exnr.1998.6778","volume":"150","author":"Singhrao S.K.","year":"1998","unstructured":"Singhrao S.K.; Thomas P.; Wood J.D.; Huntingtin protein colocalizes with lesions of neurodegenerative diseases: An investigation in Huntington\u2019s, Alzheimer\u2019s, and Pick\u2019s diseases. Exp Neurol 1998,150(2),213-222","journal-title":"Exp Neurol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s004060050101","volume":"249","author":"F\u00f6rstl H.","year":"1999","unstructured":"F\u00f6rstl H.; Kurz A.; Clinical features of Alzheimer\u2019s disease. Eur Arch Psychiatry Clin Neurosci 1999,249(6),288-290","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1750-1172-5-40","volume":"5","author":"Roos R.A.","year":"2010","unstructured":"Roos R.A.; Huntington\u2019s disease: A clinical review. Orphanet J Rare Dis 2010,5,40","journal-title":"Orphanet J Rare Dis"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrneurol.2009.218","volume":"6","author":"De Strooper B.","year":"2010","unstructured":"De Strooper B.; Vassar R.; Golde T.; The secretases: Enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol 2010,6(2),99-107","journal-title":"Nat Rev Neurol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1385\/MN:28:3:259","volume":"28","author":"Reiner A.","year":"2003","unstructured":"Reiner A.; Dragatsis I.; Zeitlin S.; Goldowitz D.; Wild-type huntingtin plays a role in brain development and neuronal survival. Mol Neurobiol 2003,28(3),259-276","journal-title":"Mol Neurobiol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1242\/dev.108712","volume":"141","author":"Nicolas M.","year":"2014","unstructured":"Nicolas M.; Hassan B.A.; Amyloid precursor protein and neural development. Development 2014,141(13),2543-2548","journal-title":"Development"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"215.e9","DOI":"10.1016\/j.neurobiolaging.2018.11.014","volume":"76","author":"Men\u00e9ndez-Gonz\u00e1lez M.","year":"2019","unstructured":"Men\u00e9ndez-Gonz\u00e1lez M.; Clarim\u00f3n J.; Rosas-Allende I.; HTT gene intermediate alleles in neurodegeneration: Evidence for association with Alzheimer\u2019s disease. Neurobiol Aging 2019,76,215.e9-215.e14","journal-title":"Neurobiol Aging"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s40478-019-0726-2","volume":"7","author":"Hartlage-R\u00fcbsamen M.","year":"2019","unstructured":"Hartlage-R\u00fcbsamen M.; Ratz V.; Zeitschel U.; Endogenous mouse huntingtin is highly abundant in cranial nerve nuclei, co-aggregates to Abeta plaques and is induced in reactive astrocytes in a transgenic mouse model of Alzheimer\u2019s disease. Acta Neuropathol Commun 2019,7(1),79","journal-title":"Acta Neuropathol Commun"},{"key":"ref=24","first-page":"487","volume":"28","author":"Wood T.E.","year":"2019","unstructured":"Wood T.E.; Barry J.; Yang Z.; Cepeda C.; Levine M.S.; Gray M.; Mutant huntingtin reduction in astrocytes slows disease progression in the BACHD conditional Huntington\u2019s disease mouse model. Hum Mol Genet 2019,28(3),487-500","journal-title":"Hum Mol Genet"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"22480","DOI":"10.1073\/pnas.0911503106","volume":"106","author":"Bradford J.","year":"2009","unstructured":"Bradford J.; Shin J-Y.; Roberts M.; Wang C-E.; Li X-J.; Li S.; Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc Natl Acad Sci USA 2009,106(52),22480-22485","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=26","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.00669","volume":"13: 669","author":"Garcia V.J.","year":"2019","unstructured":"Garcia V.J.; Rushton D.J.; Tom C.M.;  Huntington\u2019s disease patient-derived astrocytes display electrophysiological impairments and reduced neuronal support  Front Neurosci 2019,13: 669","journal-title":"Huntington\u2019s disease patient-derived astrocytes display electrophysiological impairments and reduced neuronal support  Front Neurosci"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1212\/WNL.39.9.1159","volume":"39","author":"Morris J.C.","year":"1989","unstructured":"Morris J.C.; Heyman A.; Mohs R.C.; The consortium to establish a registry for Alzheimer\u2019s Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer\u2019s disease. Neurology 1989,39(9),1159-1165","journal-title":"Neurology"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1006\/neur.1996.0057","volume":"5","author":"Mann D.M.","year":"1996","unstructured":"Mann D.M.; Pyramidal nerve cell loss in Alzheimer\u2019s disease. Neurodegeneration 1996,5(4),423-427","journal-title":"Neurodegeneration"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0070-2153(06)75002-5","volume":"75","author":"Cowan C.M.","year":"2006","unstructured":"Cowan C.M.; Raymond L.A.; Selective neuronal degeneration in Huntington\u2019s disease. Curr Top Dev Biol 2006,75,25-71","journal-title":"Curr Top Dev Biol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1126\/science.7046051","volume":"217","author":"Bartus R.T.","year":"1982","unstructured":"Bartus R.T.; Dean R.L.; Beer B.; Lippa A.S.; The cholinergic hypothesis of geriatric memory dysfunction. Science 1982,217(4558),408-414","journal-title":"Science"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2174\/1570159X13666150716165726","volume":"14","author":"Ferreira-Vieira T.H.","year":"2016","unstructured":"Ferreira-Vieira T.H.; Guimaraes I.M.; Silva F.R.; Ribeiro F.M.; Alzheimer\u2019s disease: Targeting the cholinergic system. Curr Neuropharmacol 2016,14(1),101-115","journal-title":"Curr Neuropharmacol"},{"key":"ref=32","doi-asserted-by":"publisher","DOI":"10.3389\/fncir.2017.00102","volume":"11: 102.","author":"Dannenberg H.","year":"2017","unstructured":"Dannenberg H.; Young K.; Hasselmo M.;  Modulation of hippocampal circuits by muscarinic and nicotinic receptors  Front Neural Circuits 2017,11: 102.","journal-title":"Modulation of hippocampal circuits by muscarinic and nicotinic receptors  Front Neural Circuits"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40478-015-0187-1","volume":"3","author":"Arendt T.","year":"2015","unstructured":"Arendt T.; Br\u00fcckner M.K.; Morawski M.; J\u00e4ger C.; Gertz H-J.; Early neurone loss in Alzheimer\u2019s disease: Cortical or subcortical? Acta Neuropathol Commun 2015,3,10","journal-title":"Acta Neuropathol Commun"},{"key":"ref=34","doi-asserted-by":"publisher","DOI":"10.3389\/fncir.2013.00019","volume":"7: 19.","author":"Estrada-S\u00e1nchez A.M.","year":"2013","unstructured":"Estrada-S\u00e1nchez A.M.; Rebec G.V.;  Role of cerebral cortex in the neuropathology of Huntington\u2019s disease Front Neural Circuits 2013,7: 19.","journal-title":"Role of cerebral cortex in the neuropathology of Huntington\u2019s disease Front Neural Circuits"},{"key":"ref=35","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2019.00258","volume":"12: 258.","author":"Palpagama T.H.","year":"2019","unstructured":"Palpagama T.H.; Waldvogel H.J.; Faull R.L.M.; Kwakowsky A.;  The role of microglia and astrocytes in Huntington\u2019s disease  Front Mol Neurosci 2019,12: 258.","journal-title":"The role of microglia and astrocytes in Huntington\u2019s disease  Front Mol Neurosci"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/978-981-13-9913-8_14","volume":"1175","author":"Gray M.","year":"2019","unstructured":"Gray M.; Astrocytes in Huntington\u2019s Disease. Adv Exp Med Biol 2019,1175,355-381","journal-title":"Adv Exp Med Biol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.neures.2017.11.012","volume":"126","author":"Chun H.","year":"2018","unstructured":"Chun H.; Lee C.J.; Reactive astrocytes in Alzheimer\u2019s disease: A double-edged sword. Neurosci Res 2018,126,44-52","journal-title":"Neurosci Res"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1242\/dmm.002451","volume":"2","author":"Ehrnhoefer D.E.","year":"2009","unstructured":"Ehrnhoefer D.E.; Butland S.L.; Pouladi M.A.; Hayden M.R.; Mouse models of Huntington disease: Variations on a theme. Dis Model Mech 2009,2(3-4),123-129","journal-title":"Dis Model Mech"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/0896-6273(95)90106-X","volume":"15","author":"Aronin N.","year":"1995","unstructured":"Aronin N.; Chase K.; Young C.; CAG expansion affects the expression of mutant Huntingtin in the Huntington\u2019s disease brain. Neuron 1995,15(5),1193-1201","journal-title":"Neuron"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1093\/hmg\/8.9.1647","volume":"8","author":"Boutell J.M.","year":"1999","unstructured":"Boutell J.M.; Thomas P.; Neal J.W.; Aberrant interactions of transcriptional repressor proteins with the Huntington\u2019s disease gene product, huntingtin. Hum Mol Genet 1999,8(9),1647-1655","journal-title":"Hum Mol Genet"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1093\/hmg\/ddg156","volume":"12","author":"Xia J.","year":"2003","unstructured":"Xia J.; Lee D.H.; Taylor J.; Vandelft M.; Truant R.; Huntingtin contains a highly conserved nuclear export signal. Hum Mol Genet 2003,12(12),1393-1403","journal-title":"Hum Mol Genet"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.1073\/pnas.96.8.4604","volume":"96","author":"Scherzinger E.","year":"1999","unstructured":"Scherzinger E.; Sittler A.; Schweiger K.; Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: Implications for Huntington\u2019s disease pathology. Proc Natl Acad Sci USA 1999,96(8),4604-4609","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3233\/JAD-200028","volume":"75","author":"Schedin-Weiss S.","year":"2020","unstructured":"Schedin-Weiss S.; Nilsson P.; Sandebring-Matton A.; Proteomics time-course study of App knock-in mice reveals novel presymptomatic A\u03b242-induced pathways to Alzheimer\u2019s disease pathology. J Alzheimers Dis 2020,75(1),321-335","journal-title":"J Alzheimers Dis"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1159\/000121389","volume":"5","author":"Debatin L.","year":"2008","unstructured":"Debatin L.; Streffer J.; Geissen M.; Matschke J.; Aguzzi A.; Glatzel M.; Association between deposition of beta-amyloid and pathological prion protein in sporadic Creutzfeldt-Jakob disease. Neurodegener Dis 2008,5(6),347-354","journal-title":"Neurodegener Dis"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/j.1750-3639.2000.tb00269.x","volume":"10","author":"Hamilton R.L.","year":"2000","unstructured":"Hamilton R.L.; Lewy bodies in Alzheimer\u2019s disease: A neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol 2000,10(3),378-384","journal-title":"Brain Pathol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s004010050870","volume":"96","author":"Hainfellner J.A.","year":"1998","unstructured":"Hainfellner J.A.; Wanschitz J.; Jellinger K.; Liberski P.P.; Gullotta F.; Budka H.; Coexistence of Alzheimer-type neuropathology in Creutzfeldt-Jakob disease. Acta Neuropathol 1998,96(2),116-122","journal-title":"Acta Neuropathol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1007\/s00018-006-6242-0","volume":"63","author":"Borrell-Pag\u00e8s M.","year":"2006","unstructured":"Borrell-Pag\u00e8s M.; Zala D.; Humbert S.; Saudou F.; Huntington\u2019s disease: From huntingtin function and dysfunction to therapeutic strategies. Cell Mol Life Sci 2006,63(22),2642-2660","journal-title":"Cell Mol Life Sci"},{"key":"ref=48","first-page":"65","volume":"5","author":"Schulte J.","year":"2011","unstructured":"Schulte J.; Littleton J.T.; The biological function of the Huntingtin protein and its relevance to Huntington\u2019s Disease pathology. Curr Trends Neurol 2011,5,65-78","journal-title":"Curr Trends Neurol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1093\/hmg\/ddm217","volume":"16","author":"Atwal R.S.","year":"2007","unstructured":"Atwal R.S.; Xia J.; Pinchev D.; Taylor J.; Epand R.M.; Truant R.; Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. Hum Mol Genet 2007,16(21),2600-2615","journal-title":"Hum Mol Genet"},{"key":"ref=50","unstructured":"A study to evaluate the efficacy and safety of intrathecally administered RO7234292 (RG6042) in patients with manifest Huntington\u2019s disease. Available from:"},{"key":"ref=51","unstructured":"Safety and proof-of-concept (POC) study with amt-130 in adults with early manifest Huntington disease."}],"container-title":["Current Alzheimer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/188647","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/188647\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/188647","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,5]],"date-time":"2021-12-05T09:24:46Z","timestamp":1638696286000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/188647\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,15]]},"references-count":51,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,1,15]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1567205017666201203125622","relation":{},"ISSN":["1567-2050"],"issn-type":[{"value":"1567-2050","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,15]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-03-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}